Compare TMP & FTRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TMP | FTRE |
|---|---|---|
| Founded | 1836 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.3B |
| IPO Year | 1996 | 2023 |
| Metric | TMP | FTRE |
|---|---|---|
| Price | $100.99 | $17.79 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 9 |
| Target Price | ★ $87.00 | $14.06 |
| AVG Volume (30 Days) | 83.7K | ★ 1.6M |
| Earning Date | 04-24-2026 | 05-05-2026 |
| Dividend Yield | ★ 3.21% | N/A |
| EPS Growth | ★ 126.16 | N/A |
| EPS | ★ 3.86 | N/A |
| Revenue | $75,742,000.00 | ★ $2,723,400,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $7.94 | $3.09 |
| P/E Ratio | $25.99 | ★ N/A |
| Revenue Growth | N/A | ★ 1.00 |
| 52 Week Low | $61.88 | $7.40 |
| 52 Week High | $102.02 | $21.39 |
| Indicator | TMP | FTRE |
|---|---|---|
| Relative Strength Index (RSI) | 61.77 | 46.68 |
| Support Level | $91.10 | $17.37 |
| Resistance Level | $102.02 | $17.81 |
| Average True Range (ATR) | 2.27 | 1.33 |
| MACD | -0.17 | -0.20 |
| Stochastic Oscillator | 81.69 | 6.04 |
Tompkins Financial Corp is a Financial Holding Company. The company manages its operations through two business segments, consisting of banking and wealth management. It offers various products and services, including commercial and consumer banking, leasing, trust and investment management, financial planning and wealth management, and insurance. Wealth management activities include the results of the company's trust, financial planning, and wealth management services. The company generates the majority of its revenue from the Banking segment.
Fortrea is a global, late-stage contract research organization that provides comprehensive phase 1 through phase 4 clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion.